Acute coronary syndrome (ACS) encompasses the spectrum of unstable angina and myocardial infarction, with or without ST elevation.
Percutaneous coronary intervention (PCI) including coronary stenting is often performed in this context. Both ACS and PCI are associated with high levels of platelet activation, and thus dual-antiplatelet therapy with aspirin and clopidogrel is essential after coronary stent implantation to reduce the risk of thrombosis.
A longer duration of dual-antiplatelet therapies is often required after implantation of drug-eluting stents due to delayed endothelialisation, but the optimal duration of dual antiplatelet therapies and the associated risk-benefit ratio is not well defined.
A joint initiative of the Patient Services Section and the Drug and Therapeutics Information Service of the Pharmacy Department, Repatriation General Hospital, Daw Park, South Australia. The RGH Pharmacy E-Bulletin is distributed in electronic format on a weekly basis, and aims to present concise, factual information on issues of current interest in therapeutics, drug safety and cost-effective use of medications.
Editor: Assoc. Prof. Chris Alderman, University of South Australia – Director of Pharmacy, RGH © Pharmacy Department, Repatriation General Hospital, Daw Park, South Australia 5041.